RT Journal Article
SR Electronic
A1 Shuman, Jill
T1 Brilacidin
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 48
SP 11
OP 11
DO 10.1177/1559897715591481
UL http://mdc.sagepub.com/content/15/48/11.2.abstract
AB Brilacidin is a novel host defense protein being studied for the treatment of community-acquired skin and soft tissue infections. A phase 2b trial shows that a single-dose injection of brilacidin is as effective as a 7-day dose of daptomycin in treating acute bacterial skin and skin structure infections associated with Staphylococcus aureus.